Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifetroban - Cumberland Pharmaceuticals

Drug Profile

Ifetroban - Cumberland Pharmaceuticals

Alternative Names: BMS 18029; BMS 180291; BMS 180291A; BMS-180291-02; Boxaban; CPI 211; Dyscorban; Hepatoren; Portaban; Vasculan

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cumberland Pharmaceuticals; Vanderbilt-Ingram Cancer Center
  • Class Antiasthmatics; Antifibrotics; Antihypertensives; Antineoplastics; Antiplatelets; Heterocyclic bicyclo compounds; Oxazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Cardiomyopathies; Cardiovascular disorders; Hepatorenal syndrome; Idiopathic pulmonary fibrosis; Portal hypertension; Solid tumours; Systemic scleroderma
  • Preclinical Interstitial lung diseases
  • Discontinued Coronary thrombosis; Peripheral vascular disorders; Thrombosis

Most Recent Events

  • 31 Jan 2024 Phase-II clinical trials in Idiopathic pulmonary fibrosis in USA (PO) (NCT05571059)
  • 08 Nov 2023 US FDA approves IND application for Ifetroban in Idiopathic Pulmonary Fibrosis
  • 08 Aug 2023 US FDA grants two innovation-based waivers for prescription drug program fees in Q2 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top